Fig. 7: Summary of molecular characteristics and potential therapeutic vulnerabilities in NE and non-NE SCNC.

Subtype-specific upregulated genes, IHC markers, signaling pathways, genomic alterations, therapeutic vulnerability, and resistance are displayed.